Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCCP Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCCP [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own- Shs Outstand12.50M Perf Week0.67%
Market Cap66.81M Forward P/E- EPS next Y- Insider Trans- Shs Float10.16M Perf Month-4.44%
Income- PEG- EPS next Q- Inst Own0.69% Short Float0.02% Perf Quarter-17.76%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.36 Perf Half Y-10.91%
Book/sh1.38 P/B3.87 EPS next Y- ROA- Target Price- Perf Year-16.21%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.85 - 7.00 Perf YTD-14.47%
Dividend0.60 P/FCF- EPS past 5Y- ROI- 52W High-24.29% Beta-
Dividend %11.22% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low9.28% ATR0.32
Employees12 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)45.51 Volatility1.11% 2.97%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.67 Prev Close5.35
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.40K Price5.30
Recom- SMA20-2.52% SMA50-3.50% SMA200-14.82% Volume600 Change-0.85%
Mar-25-19 07:00AM  Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor GlobeNewswire
Mar-20-19 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +8.22%
Mar-13-19 07:00AM  Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 GlobeNewswire
Mar-05-19 07:00AM  Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-05-19 07:00AM  Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-07-19 07:00AM  Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 GlobeNewswire -9.77%
Dec-27-18 07:00AM  Cyclacel Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco GlobeNewswire
Nov-12-18 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire +11.13%
Nov-06-18 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results GlobeNewswire
Oct-23-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-04-18 07:00AM  Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies GlobeNewswire
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.